+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Laboratory and clinical studies of ceftazidime in the pediatric field



Laboratory and clinical studies of ceftazidime in the pediatric field



Japanese Journal of Antibiotics 37(3): 512-523



The authors have carried out the laboratory and clinical studies of ceftazidime ( CAZ ) and obtained the following results. The antibacterial activities of CAZ against the clinical isolates of S. aureus, E. coli, K. pneumoniae, E. cloacae, E. aerogenes, S. marcescens, C. freundii and P. aeruginosa were measured by the plate dilution method with inoculum size of 10(6) cells/ml. The susceptibility distribution of S. aureus to CAZ ranged from 3.13 to 100 micrograms/ml, and the peak of distribution was 12.5 micrograms/ml. The peak of susceptibility distribution of E. coli, K. pneumoniae and E. cloacae was 0.2 micrograms/ml, and the distribution of E. aerogenes ranged from 0.1 to 100 micrograms/ml and that of S. marcescens, from 0.05 to 3.13 micrograms /ml. The growth of 92% of P. aeruginosa was inhibited at the concentration of 3.13 micrograms/ml or lower. For pharmacokinetic study, CAZ was given in a single dose of 10 mg/kg by intravenous administration for 5 minutes in 1 child and by drip infusion for 30 minutes in 2 children. After intravenous administration of CAZ , the serum level got to the peak of 41.0 micrograms/ml at 15 minutes, and was 1.0 micrograms /ml at 6 hours. Half-life time was 1.30 hours. With drip infusion of CAZ , the mean peak serum level was 52.45 +/- 2.05 micrograms/ml on completion of the infusion, and 1.05 +/- 0.05 micrograms/ml at 6 hours. Half-life time was 1.30 hours. CAZ was effective in 9 cases out of 11 cases with bacterial infection. No side effect was observed except for elevation of serum GOT and GPT in 1 case and eosinophilia in 1 case.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 043505340

Download citation: RISBibTeXText

PMID: 6376859


Related references

Clinical studies of ceftazidime in the pediatric field. Japanese Journal of Antibiotics 37(3): 460-468, 1984

Clinical studies on ceftazidime in the pediatric field. Japanese Journal of Antibiotics 37(3): 349-354, 1984

Fundamental and clinical studies of ceftazidime in the pediatric field. Japanese Journal of Antibiotics 37(3): 537-553, 1984

Basic and clinical studies on ceftazidime in the pediatric field. Japanese Journal of Antibiotics 37(3): 389-406, 1984

Laboratory and clinical studies on ceftazidime in the field of pediatrics. Japanese Journal of Antibiotics 37(3): 469-484, 1984

Laboratory and clinical studies of PC-904 in pediatric field. Japanese Journal of Antibiotics 31(7): 359-362, 1978

Laboratory and clinical studies of cefminox in the pediatric field. Japanese Journal of Antibiotics 38(3): 730-736, 1985

Laboratory and clinical studies on norfloxacin in the pediatric field. Japanese Journal of Antibiotics 43(5): 808-825, 1990

Laboratory and clinical studies of cefmenoxime in the pediatric field. Japanese Journal of Antibiotics 35(11): 2535-2544, 1982

Laboratory and clinical studies of 9,3"-diacetylmidecamycin in the pediatric field. Japanese Journal of Antibiotics 35(6): 1475-1492, 1982

Laboratory and clinical studies of cefoperazone in pediatric field. Japanese Journal of Antibiotics 33(9): 899-909, 1980

Laboratory and clinical studies on cefamandole in pediatric field. Japanese Journal of Antibiotics 32(11): 1091-1100, 1979

Laboratory and clinical studies of 6059-S in pediatric field. Japanese Journal of Antibiotics 34(5): 800-816, 1981

Laboratory and clinical studies of cefprozil in pediatric field. Japanese Journal of Antibiotics 45(11): 1582-1591, 1992

Laboratory and clinical studies on S-1108 in the pediatric field. Japanese Journal of Antibiotics 46(11): 967-977, 1993